PharmaShots | Incisive News in 3 Shots

Subscribe Now

ESMO 2021

Biocad Presents Results of BCD-021 (biosimilar, bevacizumab) in P-III Study for the Treatment of NSCLC at ESMO 2021

Biocad Presents Results of BCD-021 (biosimilar, bevacizumab) in P-III Study for the Treatment of NSCLC at ESMO 2021

October 27, 2021

$Exelixis Presents Results of Cabometyx (cabozantinib) in P-III COSMIC-311 Trial for the Treatment of Radioactive Iodine-Refractory DTC at ESMO 2021$

Exelixis Presents Results of Cabometyx (cabozantinib) in P-III COSMIC-311 Trial for the Treatment of Radioactive Iodine-Refractory...

September 22, 2021

Regeneron and Sanofi Present Results of Libtayo (cemiplimab) in P-III EMPOWER-Lung 3 Study as 1L Treatment of Advanced NSCLC at ESMO 2021

Regeneron and Sanofi Present Results of Libtayo (cemiplimab) in P-III EMPOWER-Lung 3 Study as 1L Treatment of Advanced NSCLC at ES...

September 20, 2021

Tanvex Presents Results of TX05 (biosimilar- trastuzumab) in P-III Study for the Treatment of HER2-Positive Early Stage Breast Cancer at ESMO 2021

Tanvex Presents Results of TX05 (biosimilar- trastuzumab) in P-III Study for the Treatment of HER2-Positive Early Stage Breast Can...

September 20, 2021

Biocad Presents Results of BCD-021 (biosimilar- bevacizumab) in P-III Study for the Treatment of Non-Squamous Non-Small Cell Lung Cancer at ESMO 2021

Biocad Presents Results of BCD-021 (biosimilar- bevacizumab) in P-III Study for the Treatment of Non-Squamous Non-Small Cell Lung...

September 17, 2021

Samsung Bioepis Presents Five-year Follow-up Results of Ontruzant (biosimilar- trastuzumab) in Early or Locally Advanced HER2 Positive Breast Cancer at ESMO 2021

Samsung Bioepis Presents Five-year Follow-up Results of Ontruzant (biosimilar- trastuzumab) in Early or Locally Advanced HER2 Posi...

September 12, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us